Allarity Therapeutics, Inc. (ALLR.US), a clinical-stage biopharmaceutical company, has filed an amendment with the Securities and Exchange Commission (SEC) on April 17, 2024, for a registration statement related to the issuance of 5,000,000 shares of common stock. The company's shares are listed on Nasdaq under the symbol 'ALLR.' The registration statement includes a prospectus that provides detailed information about the offering, the company's business, financial statements, and the risks involved in investing in the company. The offering is subject to various terms and conditions, including the approval of legal matters by the underwriters' counsel and other customary closing conditions. The underwriters have the option to purchase additional shares to cover over-allotments. The proceeds from the offering are intended...Show More

Allarity Therapeutics, Inc. (ALLR.US), a clinical-stage biopharmaceutical company, has filed an amendment with the Securities and Exchange Commission (SEC) on April 17, 2024, for a registration statement related to the issuance of 5,000,000 shares of common stock. The company's shares are listed on Nasdaq under the symbol 'ALLR.' The registration statement includes a prospectus that provides detailed information about the offering, the company's business, financial statements, and the risks involved in investing in the company. The offering is subject to various terms and conditions, including the approval of legal matters by the underwriters' counsel and other customary closing conditions. The underwriters have the option to purchase additional shares to cover over-allotments. The proceeds from the offering are intended for general corporate purposes, including clinical trials, working capital, and other business needs. The company has also entered into agreements with the underwriters regarding the offering price, underwriting discounts, and indemnification provisions. The filing follows a series of financial activities by Allarity Therapeutics, including previous securities offerings and agreements with investors such as 3i, LP.